loading
loading
D2C nutrition brand Ace Blend has raised $9.9 Mn in a Series A2 round led by 3one4 Capital, with participation from existing investor Fireside Ventures The startup plans to commission clinical trials to support its supplement claims and introduce automated batch testing for nutritional accuracy, pesticide residues, and heavy metals Ace Blend claims a repeat purchase rate of nearly 48% and is targeting ₹250–300 Cr in annual recurring revenue over the next 12–18 months D2C nutrition and dietary supplements brand Ace Blend has raised $9.9 Mn (about ₹95 Cr) in a Series A2 funding round led by 3one4 Capital, with participation from existing investor Fireside Ventures. The startup will use the fresh capital for clinical trials, supply chain improvements, R&D, and new nutrition formats. “The first is clinical trials, which are going to be run by credible CROs (contract research organisations) and are intended to be published in peer-reviewed international journals. The second is cementing our moat as a business, which is our supply chain proficiency. The third is a robust testing mechanism that allows nutritional accuracy, pesticides and heavy metals to be tested batch on batch without any human intervention,” founder and CEO Shivam Hingorani told Inc42. Ace Blend also plans to conduct shelf-stability studies at launch and six months later, which Hingorani said would help build long-term safety data on its products. “Trust is not enough” in the nutritional supplements market, he said, stressing the need for scientific evidence to support product claims. Founded in 2018 by Hingorani, and later joined by Saif Mehkri as cofounder in 2022, Ace Blend offers supplements across heart health, brain health, sleep, recovery, gut health, strength and immunity. Its portfolio comprises around 14 SKUs, including plant-based protein powders, superfood mixes, and functional health supplements. Besides its website, the startup sells its products through ecommerce and quick commerce platforms, including Amazon, Flipkart, Zepto, and Blinkit. Its website contributes around 50% of revenue, with the remainder coming from marketplaces and other ecommerce channels, Hingorani said. Ace Blend clocked 300% growth in FY26 and has a repeat purchase rate of nearly 48%, according to Hingorani. It is targeting annual recurring revenue of ₹250-300 Cr over the next 12-18 months, with profitability also in sight, he added. The startup plans to strengthen its supply chain by sourcing raw materials from multiple countries. Hingorani said its vertically integrated model covers ingredient sourcing, formulation, and manufacturing, while automated testing will assess nutritional accuracy, pesticide residues, and heavy metals in each batch. Ace Blend is also developing new products, including a formulation created with a gut-health specialist to address leaky gut, a combination of natural nutrients intended to lower inflammation, an eye-health product, and a fibre-based format for gut health, he said. India’s dietary supplements market is growing as consumers become more aware of preventive healthcare and the role of supplements in managing chronic conditions. Investor interest in the sector is also rising. Earlier this month, D2C brand The Stack raised ₹21.5 Cr to expand its product range and invest in R&D. According to Grand View Research, India’s dietary supplements market was valued at $5.8 Bn in 2025. It is projected to reach $6.6 Bn in 2026 and $12.4 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.5% between 2026 and 2033.
document fetched 2026-10-30 02:57 · canonical https://inc42.com/buzz/ace-blend-raises-9-9-mn-to-fund-clinical-trials-expand-nutrition-portfolio